Crescent Capital Partners
Yan Messoussa is a Private Equity Associate at Crescent Capital Partners, where responsibilities include generalist private equity since August 2022. Prior experience includes serving as a Private Equity Senior Analyst and Investment Banking Analyst at Macquarie Group from July 2021 to June 2022, focusing on infrastructure principal investing. Yan also held the role of Chief Operating Officer at Global Platinum Securities, an inter-collegiate investment fund recruiting talents from leading institutions such as LSE, Harvard, MIT, and Wharton from January 2020 to January 2021. Earlier, a summer analyst role in investment banking was completed at Macquarie Group in July 2020. Educational background includes a BSc in Finance from The London School of Economics and Political Science (LSE), graduated in July 2021.
This person is not in any teams
Crescent Capital Partners
Crescent Capital Partners (Crescent) is a Sydney-based private equity firm investing in middle-market companies located in Australia and New Zealand with enterprise values between A$100 million and A$500 million. Crescent was formed in 2000 and has established itself as one of Australasia’s leading middle market private equity firms with its last three funds ranked as top quartile global funds (measured in either USD or AUD), as measured by Cambridge Associates. Crescent’s investment focus is on high-growth companies and sectors, or in industries that are undergoing structural change or that lend themselves to consolidation. Crescent’s role is to accelerate and support the senior management teams of these businesses in reaching their aspirational targets and goals. Crescent has a differentiated investment process that combines thematic and proprietary deal sourcing, with a disciplined and analytical approach to investing and a proactive approach to driving value at portfolio companies. Crescent has particular experience and skills in financial services, healthcare, branded and industrial businesses. In particular, Crescent has been the most active private equity manager in healthcare transactions in Australia measured by number of investments made in the past 10 years. Crescent has had a strong track record in delivering superior returns to investors through successful exits. Crescent is now investing our $1 billion Crescent VII (2023 vintage).